Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07721233

Virtual-reality Induced Immune Modulation in Allergic Patients

This study investigates whether immersive virtual reality (VR) exposure to allergen-related stimuli can modulate behavioural, neurophysiological, psychophysiological, and immune responses in adults with bee or wasp venom allergy.

The study consists of two parts. In Part 1, adults with documented bee or wasp venom allergy and healthy volunteers will undergo immersive VR exposure in a realistic picnic environment. All participants will first be exposed to a control condition involving virtual flies. They will then be randomly assigned to exposure to either virtual bees or wasps or a control condition involving virtual flies. During the VR sessions, behavioural responses, heart rate and heart-rate variability, skin conductance, pupil dilation, temperature, and electroencephalographic activity will be recorded. Blood samples will be collected before and after VR exposure to assess changes in basophil activation and other immunological markers.

In Part 2, patients receiving standard-of-care venom immunotherapy will be followed longitudinally. Blood samples will be collected before and during treatment to characterize immunological changes associated with venom desensitization. After approximately six months of venom immunotherapy, participants will undergo a further VR session involving either virtual bees or wasps or virtual flies. Behavioural, psychophysiological, neurophysiological, and immunological assessments will be repeated to determine whether venom immunotherapy reduces responses to virtual allergen-related stimuli.

The primary outcome is the change in basophil activation, measured as the percentage of CD63-positive circulating basophils. Secondary outcomes include changes in circulating type 2 innate lymphoid cells and regulatory T cells, serum IL-13 and tryptase concentrations, reaction times, cardiovascular and autonomic responses, pupil dilation, skin temperature, and electroencephalographic responses.

The study does not involve exposure to real insects or venom as part of the investigational VR procedure. Its aim is to improve understanding of brain-immune interactions in allergy and to provide preliminary evidence for the potential future use of VR-based approaches alongside conventional allergy treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hymenoptera Venom Allergy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Able to understand the participant information and provide written informed consent.
  • Willing and able to comply with all study procedures.

Part 1 - Healthy volunteers

  • No known bee or wasp venom allergy.
  • No current allergen immunotherapy or monoclonal antibody treatment.
  • No known active allergic, autoimmune, inflammatory, or immunodeficiency disorder requiring systemic treatment.

Part 1 - Participants with bee or wasp venom allergy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • No ongoing venom immunotherapy at the time of inclusion in Part 1.
  • No current monoclonal antibody treatment or systemic immunosuppressive treatment at the time of testing.

Part 2 - Participants undergoing venom immunotherapy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • Planned initiation of or ongoing treatment with standard-of-care venom immunotherapy.

Exclusion criteria

  • Absence of written informed consent.
  • Inability to understand the study information or provide informed consent.
  • Age younger than 18 years.
  • Current systemic immunosuppressive therapy.
  • Current monoclonal antibody treatment for an allergic, autoimmune, or inflammatory disease at the time of testing.
  • Ongoing allergen immunotherapy for allergies other than bee or wasp venom allergy.
  • Leukocyte count below 3.5 G/L.
  • Hemoglobin below approximately 120 g/L in women or below approximately 130 g/L in men.
  • Bee or wasp sting reaction within the previous 2 months.
  • Intolerance to virtual reality, as assessed during a preliminary interview

Treatment and study plan

Allergen-related immersive virtual reality exposure

Behavioral

Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual bees or wasps progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief stimulus is delivered to simulate a sting.

Control immersive virtual reality exposure

Behavioral

Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual flies progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief synchronized stimulus is delivered to simulate touch or tickling. In Part 1, this intervention is administered to all participants as the initial baseline exposure and is repeated in participants assigned to the control condition.

Primary outcomes

  1. Change in Percentage of CD63-Positive Circulating Basophils Following Virtual-Reality Exposure in Part 1

    Time frame: T0, 10 minutes after the initial fly exposure, to T2, 40 minutes after the second VR exposure; same study day

  2. Change in Percentage of CD63-Positive Circulating Basophils During Venom Immunotherapy and Subsequent Virtual-Reality Exposure in Part 2

    Time frame: Before initiation of venom immunotherapy at T0 to 40 minutes after VR exposure at approximately month 7 at T5

Study contacts

Contact information is provided by the study sponsor or research team.

Camilla Jandus

CONTACT

[email protected]

+41 22 379 54 40

Peter Jandus

CONTACT

[email protected]

+41 22 372 93 82

Sponsors and collaborators

Lead sponsor

University of Geneva, Switzerland

Other

Registry information

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jul 23, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.